Abstract
Developing messenger RNA (mRNA) vaccines for COVID-19 renewed and intensified the interest in using mRNA for disease prevention and treatment. Despite their efficacy, linear mRNA molecules are short-lived in the human body, primarily due to enzymatic degradation at the free ends. In contrast, circular RNA (circRNA) exhibits enhanced stability and resistance to exonuclease degradation. However, this stability depends highly on purity. Unfortunately, the in vitro transcription/self-splicing reaction products contain a mixture of circular and linear RNAs. Yet, practical methods for purifying circRNA from solutions containing linear RNA contaminants are lacking. In this study, we explored the feasibility of using ultrafiltration to purify protein-encoding circRNA produced by the self-splicing of a precursor RNA (preRNA) during in vitro transcription (IVT). We measured the sieving coefficients, a separation metric, of circRNA, linear precursor RNA, and nicked RNA conformers using polyethersulfone membranes with molecular weight cutoffs from 30 to 300 kDa, analyzing performance as a function of permeate flux. We also estimated the RNA critical fluxes and determined suitable operating conditions for purification. We achieved a purity of 86% with a yield above 50%. By comparison, the purity achieved by size-exclusion high-performance liquid chromatography (SE-HPLC), the leading alterative separation technology, was 41% with a yield of 45%. These findings highlight ultrafiltration as a superior method for purifying circRNA at the research scale. Its scalability suggests that it could play a critical role in enabling the large-scale manufacturing of circRNA-based therapeutics.
Full Text Availability
The license terms selected by the author(s) for this preprint version do not permit archiving in PMC. The full text is available from the preprint server.